Is Onzima's placing the most expensive ever?
Shareholders of Onzima Ventures (ONZ) will be breathing a sigh of relief following confirmation of the acquisition of the remaining 51% of private company N4 Pharma, and meaning that the new entity will relist on AIM. This won’t have come as a massive surprise as the company announced this proposed acquisition back in January, but some still seemed nervous as the announcement went right down to the wire in terms of Onzima either announcing such a deal (which constitutes a reverse takeover) or being booted off of AIM.

